Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00678392
Registration number
NCT00678392
Ethics application status
Date submitted
12/05/2008
Date registered
15/05/2008
Date last updated
9/01/2019
Titles & IDs
Public title
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Query!
Scientific title
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Query!
Secondary ID [1]
0
0
AXIS TRIAL
Query!
Secondary ID [2]
0
0
A4061032
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Kidney Neoplasms
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Kidney
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Axitinib (AG-013736)
Treatment: Drugs - Sorafenib
Experimental: Axitinib -
Active Comparator: Sorafenib -
Treatment: Drugs: Axitinib (AG-013736)
axitinib will be given at a starting dose of 5 mg twice daily [BID] with continuous dosing
Treatment: Drugs: Sorafenib
sorafenib will be given at a dose of 400 mg twice daily [BID] with continuous dosing
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-Free Survival (PFS)
Query!
Assessment method [1]
0
0
PFS was defined as the time in months from start of study treatment to the first documentation of objective tumor progression of disease (PD) or to death due to any cause, whichever occurs first. PD was assessed by response evaluation criteria in solid tumors (RECIST) version 1.0. PD: >=20 percent (%) increase in the sum of the longest dimensions (LD) of the target lesions taking as a reference the smallest sum of the LD recorded since the start of treatment or unequivocal progression in non-target lesions or the appearance of 1 or more new lesions. Occurrence of a pleural effusion or ascites was also considered PD if demonstrated by cytological investigation and it was not previously documented. New bone lesions not previously documented were considered PD if confirmed by computed tomography/magnetic resonance imaging or X-ray.
Query!
Timepoint [1]
0
0
From initiation of treatment up to follow-up period (up to 3 years)
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS was defined as the duration from start of study treatment to date of death due to any cause. OS was calculated as (months) = (date of death minus the date of first dose of study medication plus 1) divided by 30.4. For participants who were alive, overall survival was censored on last date the participants were known to be alive.
Query!
Timepoint [1]
0
0
From initiation of treatment up to follow-up period (up to 3 years)
Query!
Secondary outcome [2]
0
0
Objective Response Rate (ORR)
Query!
Assessment method [2]
0
0
ORR = percentage of participants with confirmed complete response (CR) or confirmed partial response (PR) according to RECIST version 1.0 recorded from first dose of study treatment until PD or death due to any cause. CR: disappearance of all target, non target lesions and no appearance of new lesions, documented on 2 occasions separated by at least 4 weeks. PR: at least 30 % decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non target lesions, no appearance of new lesions. PD: >=20% increase in sum of LD of the target lesions taking as a reference smallest sum of LD recorded since the start of treatment or unequivocal progression in non-target lesions or appearance of 1 or more new lesions. Occurrence of pleural effusion or ascites if demonstrated by cytological investigation, not previously documented. New bone lesions not previously documented if confirmed by computed tomography/magnetic resonance imaging or X-ray.
Query!
Timepoint [2]
0
0
From initiation of treatment up to follow-up period (up to 3 years)
Query!
Secondary outcome [3]
0
0
Duration of Response (DR)
Query!
Assessment method [3]
0
0
DR: time from first documentation of objective tumor response (CR or PR), that was subsequently confirmed, to the first documentation of PD or to death due to any cause, whichever occurred first as per RECIST version 1.0, a) CR: disappearance of all target, non target lesions and no appearance of new lesions, documented on 2 occasions separated by at least 4 weeks, b) PR: at least 30 % decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non target lesions, no appearance of new lesions, c) PD: >=20% increase in sum of LD of the target lesions taking as a reference smallest sum of LD recorded since the start of treatment or unequivocal progression in non-target lesions or appearance of 1 or more new lesions. Occurrence of pleural effusion or ascites if demonstrated by cytological investigation, not previously documented. New bone lesions not previously documented if confirmed by computed tomography/magnetic resonance imaging or X-ray.
Query!
Timepoint [3]
0
0
From initiation of treatment up to follow-up period (up to 3 years)
Query!
Secondary outcome [4]
0
0
Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [4]
0
0
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life- threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious AEs.
Query!
Timepoint [4]
0
0
From initiation of treatment up to follow-up period (up to 3 years)
Query!
Secondary outcome [5]
0
0
Percentage of Participants With Adverse Events (AEs) by Severity
Query!
Assessment method [5]
0
0
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severity of the AEs was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Grade 1= mild; Grade 2= moderate; Grade 3= severe; Grade 4= life-threatening or disabling; Grade 5= death related to AE.
Query!
Timepoint [5]
0
0
From initiation of treatment up to follow-up period (up to 3 years)
Query!
Secondary outcome [6]
0
0
Percentage of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [6]
0
0
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life -threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both serious and non -serious AEs.
Query!
Timepoint [6]
0
0
From initiation of treatment up to follow-up period (up to 3 years)
Query!
Secondary outcome [7]
0
0
Number of Participants With Clinically Significant Laboratory Abnormalities: Hematology
Query!
Assessment method [7]
0
0
Hematology laboratory test included hemoglobin, platelet count, white blood cells count, neutrophils and lymphocytes. Abnormalities were assessed by CTCAE Grade Version 2 for severity: Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.
Query!
Timepoint [7]
0
0
From initiation of treatment up to follow-up period (up to 3 years)
Query!
Secondary outcome [8]
0
0
Number of Participants With Clinically Significant Laboratory Abnormalities: Biochemistry
Query!
Assessment method [8]
0
0
Biochemistry laboratory test included parameters: alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, bicarbonate, bilirubin, creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, hypophosphatemia and lipase. Abnormalities were assessed by CTCAE Grade Version 2 for severity: Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.
Query!
Timepoint [8]
0
0
From initiation of treatment up to follow-up period (up to 3 years)
Query!
Secondary outcome [9]
0
0
Number of Participants With Clinically Significant Laboratory Abnormalities: Urinalysis
Query!
Assessment method [9]
0
0
Urinalysis included urine blood/ hemoglobin, glucose and protein. Abnormalities were assessed by CTCAE Grade Version 2 for severity: Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.
Query!
Timepoint [9]
0
0
From initiation of treatment up to follow-up period (up to 3 years)
Query!
Secondary outcome [10]
0
0
Functional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15) Score
Query!
Assessment method [10]
0
0
FKSI was used to assess quality of life (QoL) for those diagnosed with renal cell cancer and consisted of 15 items (lack of energy, side effects, pain, losing weight, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria and sleep). Each of the 15 items was answered on a 5-point Likert-type scale ranging from 0 to 4 (0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score = sum of the 15 item scores; total range: 0 - 60; 0 (no symptoms) to 60 (very much); higher scores indicate greater presence of symptoms.
Query!
Timepoint [10]
0
0
Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)
Query!
Secondary outcome [11]
0
0
Functional Assessment of Cancer Therapy Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) Score
Query!
Assessment method [11]
0
0
FKSI-DRS was used to assess quality of life for those diagnosed with renal cell cancer and consisted of 9 items (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, and hematuria). Each of the 9 items was answered on a 5-point Likert-type scale ranging from 0 to 4 (0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI-DRS score = sum of the 9 item scores; total range: 0 - 36; 0 (no symptoms) to 36 (very much); higher scores indicate greater presence of symptoms.
Query!
Timepoint [11]
0
0
Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)
Query!
Secondary outcome [12]
0
0
Euro Quality of Life Questionnaire- 5 Dimension (EQ-5D): Health State Profile Utility Score
Query!
Assessment method [12]
0
0
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility or index score. Health state profile component assesses level of health for 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain was rated on a 3-point response scale (1= no problems, 2= some/moderate problems and 3= extreme problems). Scoring formula developed by EuroQol Group assigned a utility value for each domain in the profile. Score were transformed and resulted in a total score range of 0 to 1, with higher scores indicating better health.
Query!
Timepoint [12]
0
0
Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)
Query!
Secondary outcome [13]
0
0
Euro Quality of Life Questionnaire- 5 Dimension (EQ-5D): Visual Analog Scale (VAS)
Query!
Assessment method [13]
0
0
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. VAS component: participants rated their current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health.
Query!
Timepoint [13]
0
0
Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)
Query!
Eligibility
Key inclusion criteria
- Histologically or cytologically confirmed renal cell cancer with a component of clear
cell subtype, with metastasis
- Evidence of measurable disease
- Must have failed one prior systemic first-line regimen for metastatic renal cell
cancer
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Prior treatment for metastatic renal cell cancer with more that one systemic first
line therapy
- Major surgery less than 4 weeks or radiation less than 2 weeks of starting study drug
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
3/09/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
25/02/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
723
Query!
Recruitment in Australia
Recruitment state(s)
ACT,SA,VIC
Query!
Recruitment hospital [1]
0
0
The Canberra Hospital, Medical Oncology - Garran
Query!
Recruitment hospital [2]
0
0
Ashford Cancer Centre Research - Kurralta Park
Query!
Recruitment hospital [3]
0
0
Ballarat Oncology & Haematology Services - Ballarat
Query!
Recruitment hospital [4]
0
0
Peter MacCallum Cancer Centre - East Melbourne
Query!
Recruitment hospital [5]
0
0
Heidelberg Repatriation Hospital, Austin Health - Heidelberg West
Query!
Recruitment hospital [6]
0
0
Austin Hospital, Austin Health - Heidelberg
Query!
Recruitment postcode(s) [1]
0
0
2605 - Garran
Query!
Recruitment postcode(s) [2]
0
0
5037 - Kurralta Park
Query!
Recruitment postcode(s) [3]
0
0
3350 - Ballarat
Query!
Recruitment postcode(s) [4]
0
0
3002 - East Melbourne
Query!
Recruitment postcode(s) [5]
0
0
3081 - Heidelberg West
Query!
Recruitment postcode(s) [6]
0
0
3084 - Heidelberg
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
District of Columbia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Idaho
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Indiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Minnesota
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Missouri
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Nevada
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New Jersey
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New York
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
North Carolina
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Ohio
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Oregon
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Pennsylvania
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
South Carolina
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Tennessee
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Texas
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Virginia
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Washington
Query!
Country [25]
0
0
Austria
Query!
State/province [25]
0
0
Wien
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
RJ
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
RS
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
SP
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Alberta
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
British Columbia
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
New Brunswick
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Newfoundland and Labrador
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Ontario
Query!
Country [34]
0
0
China
Query!
State/province [34]
0
0
Chaoyang District
Query!
Country [35]
0
0
China
Query!
State/province [35]
0
0
Jiangsu
Query!
Country [36]
0
0
China
Query!
State/province [36]
0
0
P.R.
Query!
Country [37]
0
0
China
Query!
State/province [37]
0
0
Shaanxi
Query!
Country [38]
0
0
China
Query!
State/province [38]
0
0
Guangzhou
Query!
Country [39]
0
0
China
Query!
State/province [39]
0
0
Shanghai
Query!
Country [40]
0
0
China
Query!
State/province [40]
0
0
Tianjin
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Cedex 08
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Bordeaux Cedex
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
CRETEIL Cedex
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Marseille Cedex 09
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Paris Cedex 15
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Rennes
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
St Herblain Cedex
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Tours Cedex 1
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Vandoeuvre les Nancy
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Villejuif Cedex
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Aachen
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Berlin
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Essen
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Hannover
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Mainz
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Muenchen
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Oldenburg
Query!
Country [58]
0
0
Greece
Query!
State/province [58]
0
0
Attiki
Query!
Country [59]
0
0
Greece
Query!
State/province [59]
0
0
Macedonia
Query!
Country [60]
0
0
India
Query!
State/province [60]
0
0
Haryana
Query!
Country [61]
0
0
India
Query!
State/province [61]
0
0
Kerala
Query!
Country [62]
0
0
India
Query!
State/province [62]
0
0
Maharashtra
Query!
Country [63]
0
0
India
Query!
State/province [63]
0
0
Punjab
Query!
Country [64]
0
0
India
Query!
State/province [64]
0
0
Rajasthan
Query!
Country [65]
0
0
Ireland
Query!
State/province [65]
0
0
Dublin 24
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Arezzo
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Aviano (PN)
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Brescia
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
Cremona
Query!
Country [70]
0
0
Italy
Query!
State/province [70]
0
0
Genova
Query!
Country [71]
0
0
Italy
Query!
State/province [71]
0
0
Milano
Query!
Country [72]
0
0
Italy
Query!
State/province [72]
0
0
Napoli
Query!
Country [73]
0
0
Italy
Query!
State/province [73]
0
0
Padova
Query!
Country [74]
0
0
Italy
Query!
State/province [74]
0
0
Pavia
Query!
Country [75]
0
0
Italy
Query!
State/province [75]
0
0
Roma
Query!
Country [76]
0
0
Italy
Query!
State/province [76]
0
0
Rozzano (MI)
Query!
Country [77]
0
0
Japan
Query!
State/province [77]
0
0
Hokkaido
Query!
Country [78]
0
0
Japan
Query!
State/province [78]
0
0
Ibaraki
Query!
Country [79]
0
0
Japan
Query!
State/province [79]
0
0
Osaka
Query!
Country [80]
0
0
Japan
Query!
State/province [80]
0
0
Shizuoka
Query!
Country [81]
0
0
Japan
Query!
State/province [81]
0
0
Tokyo
Query!
Country [82]
0
0
Japan
Query!
State/province [82]
0
0
Yamaguchi
Query!
Country [83]
0
0
Japan
Query!
State/province [83]
0
0
Akita
Query!
Country [84]
0
0
Japan
Query!
State/province [84]
0
0
Chiba
Query!
Country [85]
0
0
Japan
Query!
State/province [85]
0
0
Fukuoka
Query!
Country [86]
0
0
Japan
Query!
State/province [86]
0
0
Kumamoto
Query!
Country [87]
0
0
Japan
Query!
State/province [87]
0
0
Tokushima
Query!
Country [88]
0
0
Japan
Query!
State/province [88]
0
0
Yamagata
Query!
Country [89]
0
0
Korea, Republic of
Query!
State/province [89]
0
0
Gyeonggi-do
Query!
Country [90]
0
0
Korea, Republic of
Query!
State/province [90]
0
0
Busan
Query!
Country [91]
0
0
Korea, Republic of
Query!
State/province [91]
0
0
Seoul
Query!
Country [92]
0
0
Poland
Query!
State/province [92]
0
0
Wielkopolska
Query!
Country [93]
0
0
Poland
Query!
State/province [93]
0
0
Gdansk
Query!
Country [94]
0
0
Poland
Query!
State/province [94]
0
0
Poznan
Query!
Country [95]
0
0
Poland
Query!
State/province [95]
0
0
Warszawa
Query!
Country [96]
0
0
Poland
Query!
State/province [96]
0
0
Wroclaw
Query!
Country [97]
0
0
Russian Federation
Query!
State/province [97]
0
0
Kaluga Region
Query!
Country [98]
0
0
Russian Federation
Query!
State/province [98]
0
0
Moscow
Query!
Country [99]
0
0
Russian Federation
Query!
State/province [99]
0
0
St. Petersburg
Query!
Country [100]
0
0
Singapore
Query!
State/province [100]
0
0
Singapore
Query!
Country [101]
0
0
Slovakia
Query!
State/province [101]
0
0
Bratislava
Query!
Country [102]
0
0
Slovakia
Query!
State/province [102]
0
0
Zilina
Query!
Country [103]
0
0
Spain
Query!
State/province [103]
0
0
Barcelona
Query!
Country [104]
0
0
Spain
Query!
State/province [104]
0
0
Navarra
Query!
Country [105]
0
0
Spain
Query!
State/province [105]
0
0
Madrid
Query!
Country [106]
0
0
Spain
Query!
State/province [106]
0
0
Malaga
Query!
Country [107]
0
0
Spain
Query!
State/province [107]
0
0
Sevilla
Query!
Country [108]
0
0
Spain
Query!
State/province [108]
0
0
Zaragoza
Query!
Country [109]
0
0
Sweden
Query!
State/province [109]
0
0
Linkoping
Query!
Country [110]
0
0
Sweden
Query!
State/province [110]
0
0
Umea
Query!
Country [111]
0
0
Sweden
Query!
State/province [111]
0
0
Vaxjo
Query!
Country [112]
0
0
Taiwan
Query!
State/province [112]
0
0
Kaohsiung Hsien
Query!
Country [113]
0
0
Taiwan
Query!
State/province [113]
0
0
Taichung
Query!
Country [114]
0
0
Taiwan
Query!
State/province [114]
0
0
Taipei
Query!
Country [115]
0
0
Taiwan
Query!
State/province [115]
0
0
Taoyuan
Query!
Country [116]
0
0
United Kingdom
Query!
State/province [116]
0
0
England
Query!
Country [117]
0
0
United Kingdom
Query!
State/province [117]
0
0
Middlesex
Query!
Country [118]
0
0
United Kingdom
Query!
State/province [118]
0
0
Bebington, Wirral
Query!
Country [119]
0
0
United Kingdom
Query!
State/province [119]
0
0
Birmingham
Query!
Country [120]
0
0
United Kingdom
Query!
State/province [120]
0
0
Bournemouth
Query!
Country [121]
0
0
United Kingdom
Query!
State/province [121]
0
0
Bristol
Query!
Country [122]
0
0
United Kingdom
Query!
State/province [122]
0
0
Cambridge
Query!
Country [123]
0
0
United Kingdom
Query!
State/province [123]
0
0
Glasgow
Query!
Country [124]
0
0
United Kingdom
Query!
State/province [124]
0
0
London
Query!
Country [125]
0
0
United Kingdom
Query!
State/province [125]
0
0
Oxford
Query!
Country [126]
0
0
United Kingdom
Query!
State/province [126]
0
0
Surrey
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pfizer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in
delaying tumor progression in patients with metastatic renal cell cancer after failure of one
first line regimen.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00678392
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00678392
Download to PDF